Navigation Links
InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application
Date:5/4/2010

ad submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA), seeking approval to market Esbriet for the treatment of IPF patients in the European Union.  Esbriet (pirfenidone) has been granted Orphan Drug status for the treatment of IPF in Europe.

About Esbriet (pirfenidone)

In February 2009, InterMune announced the results of the company's two global Phase 3 clinical trials evaluating Esbriet for the treatment of IPF, known as the CAPACITY trials.  Prior to the CAPACITY results, a Phase 3 study in IPF patients was conducted in Japan by Shionogi & Co. Ltd. which led to the marketing approval of pirfenidone in Japan in October of 2008.  In these clinical studies, Esbriet was safe and generally well tolerated with the most frequent side effects reported being photosensitivity rash and gastrointestinal symptoms.

About IPF

Idiopathic pulmonary fibrosis (IPF) is a progressive, debilitating and ultimately fatal disease that affects approximately 200,000 people in Europe and the United States combined, with approximately 30,000 new cases reported per year in each region.

IPF is characterized by inflammation and scarring (fibrosis) in the lungs, hindering the ability to process oxygen and is a progressive disease, meaning that over time, lung scarring and symptoms increase in severity.  The median survival time from diagnosis is two to five years, with a five-year survival rate of approximately 20%.  Patients diagnosed with IPF are usually between the ages of 40 and 70, with a median age of 63 years and the disease tends to affect slightly more
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. InterMune to Release First Quarter Financial Results on April 29
2. InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
3. InterMune Announces Proposed Public Offering of Common Stock
4. InterMune to Release Third Quarter Financial Results on November 5
5. InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
6. InterMune to Present at Canaccord Adams Conference
7. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
8. InterMune to Release Second Quarter Financial Results on August 6
9. InterMune to Present at Goldman Sachs Healthcare Conference
10. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
11. InterMune to Release First Quarter Financial Results on April 30
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2014)... DuPont Tate & Lyle Bio ... it has appointed Skidmore Sales & Distributing ... Essex Grain Products and Processor’s ... in the food and beverage markets. The ... mid-western states: Alabama, Arkansas, Connecticut, Delaware, Florida, ...
(Date:9/11/2014)... LONDON , Sept. 11, 2014 ... (CRT), the charity,s development and commercialisation arm, have reached ... biotechnology company in the emerging field of regenerative ... AST-VAC2 into clinical trials in subjects with non-small ... tenth treatment to enter Cancer Research UK,s Clinical ...
(Date:9/11/2014)... The Stem Cell Institute, located in ... umbilical cord stem cell therapy on Saturday, September 20, 2014 ... Resort from 1:00 pm to 4:00 pm. , Stem ... – “Umbilical Cord Stem Cell Clinical Trials for MS and ... founder of the Stem Cell Institute and Medistem Panama Inc. ...
(Date:9/10/2014)... Brunswick, New Jersey (PRWEB) September 11, 2014 ... will host its annual Innovations in Dermatological Sciences ... meeting will focus on how the university, industry ... dermatological research into clinical use. , This conference ... had experience with cross-sector collaboration, to share their ...
Breaking Biology Technology:DuPont Tate & Lyle Bio Products Appoints Skidmore Sales as Distributor for Zemea® USP 2DuPont Tate & Lyle Bio Products Appoints Skidmore Sales as Distributor for Zemea® USP 3Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 2Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 3Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 4Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 5Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 6Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 7Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 8Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in San Antonio, Texas September 20th, 2014 2Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in San Antonio, Texas September 20th, 2014 3Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in San Antonio, Texas September 20th, 2014 4Innovations in Dermatological Sciences 2014 2Innovations in Dermatological Sciences 2014 3
... N.J., March 26 Vicus Therapeutics, LLC, ... Rao, Vice President Clinical Research and Development, ... 15th International,Molecular Medicine Tri-Conference on March 28st ... Convention Center in San Francisco. Dr. Rao ...
... JOLLA, Calif., March 26 TorreyPines,Therapeutics, Inc. (Nasdaq: ... and year ended December 31, 2007. For the full ... a net loss of $23.4 million.,Cash and cash equivalents ... made meaningful progress in our three clinical development programs,in ...
... 26 Pharsight,Corporation (Nasdaq: PHST ), a leading ... clinical drug,development announced today that it will be presenting ... Conference on April 2, 2008 at the Palms Las,Vegas. ... Vice President and CFO, will be presenting on April ...
Cached Biology Technology:TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights 2TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights 3TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights 4TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights 5TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights 6TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights 7Pharsight to Present at B. Riley & Co. 9th Annual Las Vegas Investor Conference 2
(Date:9/11/2014)... DDT, American peregrine falcons ( Falco peregrines anatum ) ... stop rearing young birds in captivity and placing them ... models that year in ESA,s journal Ecological ... in California, with and without direct human intervention in ... would continue to recover without captive rearing, though the ...
(Date:9/11/2014)... 2014)Scientists today unveiled what appears to be the first ... New fossils of the massive Cretaceous-era predator reveal it ... years ago, providing the most compelling evidence to date ... an aquatic environment. The fossils also indicate that ... roam the Earth, measuring more than 9 feet longer ...
(Date:9/11/2014)... ago, a sudden, catastrophic event plunged much of the ... drought. This drastic climate changethe Younger Dryascoincided with the ... and the mastodon, and resulted in major declines in ... culture. , With limited evidence, several rival theories have ... such as a collapse of the North American ice ...
Breaking Biology News(10 mins):Volunteer 'eyes on the skies' track peregrine falcon recovery in California 2Volunteer 'eyes on the skies' track peregrine falcon recovery in California 3Volunteer 'eyes on the skies' track peregrine falcon recovery in California 4Volunteer 'eyes on the skies' track peregrine falcon recovery in California 5Scientists report first semiaquatic dinosaur, Spinosaurus 2Scientists report first semiaquatic dinosaur, Spinosaurus 3Scientists report first semiaquatic dinosaur, Spinosaurus 4Microscopic diamonds suggest cosmic impact responsible for major period of climate change 2
... A large collaborative study has added to the ... a person will be. The research, published by Cell ... of Human Genetics , identifies uncommon and previously unknown ... the genetic architecture of other complex traits. Although ...
... Most agricultural crops require large quantities of ... for growers is finding ways to balance the ... potentially harmful nitrates that can leach into ground ... "low-input" approaches is challenging researchers to identify genotypes ...
... traditionally relied heavily on hand thinning, a necessary but ... costs and a limited workforce, peach and other stone ... string thinners to minimize the need for hand thinning. ... when it was evaluated in four U.S. growing regions; ...
Cached Biology News:Large-scale analysis identifies new genetic alterations associated with height 2Improving nitrogen use efficiency lessens environmental impact 2Hybrid string blossom thinner tested in peach orchards 2
Goat anti-VAV2 Class: Antibody Product Group: Miscellaneous Antibody...
Indoleamine 2,3-dioxygenase [IDO]...
Request Info...
Pancreatic Cell Cryopreservation Medium (2X) is intended for the cryopreservation of LT2 Immortalized Pancreatic Mesenchymal Cells (SCR013) and VIT1 Primary Pancreatic Mesenchymal Cells (SCR014)....
Biology Products: